RDY

Business Context and Reporting Period

Company: Dr. Reddy's Laboratories Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Third Quarter Fiscal Year 2009 (ended December 31, 2008)
Key Event: The quarter was significantly impacted by the successful launch of the authorized generic version of GlaxoSmithKline's Imitrex (sumatriptan succinate) in late November 2008. Additionally, the company announced the appointment of Umang Vohra as the new Chief Financial Officer (CFO) and the resignation of non-executive Director Prof. Krishna G. Palepu.

Key Financial Metrics

Note: USD figures are based on a convenience translation rate of 1 USD = Rs. 48.58. PAT growth is adjusted for a one-time intangible write-down in Q3 FY08.

Material Changes vs. Prior Period

• Revenue Surge: Overall revenue grew 49% year-over-year. Excluding the new Sumatriptan product, organic growth was 21%.
• Segment Performance:
  • Global Generics: Revenue grew 70% to Rs. 13.7 billion, driven by Sumatriptan and strong performance in North America (80% growth excluding Sumatriptan) and Russia (44% growth).
  • Pharmaceutical Services & Active Ingredients (PSAI): Revenue grew 6% to Rs. 4.5 billion, though margins declined from 30% to 27% due to product mix changes and input costs.
  • India: Revenue remained flat at Rs. 2.0 billion due to a strategic shift to a replenishment-based supply chain model and delayed product launches.
  • Europe (Germany): Revenue declined marginally (2%) due to destocking ahead of the AOK tender and price erosion, despite 15% volume growth.
• Profitability: Gross margins expanded to 56% (from 49%) largely due to high margins on Sumatriptan. Operating income improved significantly to Rs. 3.0 billion from a loss of Rs. 1.8 billion in the prior year, which included a Rs. 2.9 billion one-time write-down of intangibles.
• One-Time Items: The company recorded a provision of Rs. 969 million for damages related to the German court upholding the validity of the olanzapine patent. Net finance costs increased due to a Rs. 493 million forex loss (primarily from Russian Ruble devaluation) compared to a gain in the prior year.

Guidance, Outlook, and Risks

• Guidance Update: For the 9 months of FY09, the company exceeded revenue guidance (35% growth vs. 25% target) and gross margin guidance (52% vs. 50%+). However, management stated they will be unable to meet the absolute EBITDA guidance for Germany ($39 million) due to the olanzapine withdrawal and price erosion.
• Outlook:
  • North America: Expecting continued growth driven by Para IV settlements and a pipeline of difficult-to-make generics. Goal is at least one upside opportunity with limited competition annually for the next five years.
  • Germany: Strategy shifting to "high volumes and low margins" to adapt to the tender-based model. Management aims to maintain overall revenue levels in FY10 despite potential impairment charges on top products.
  • India: Anticipating a resurgence in sales starting in the next fiscal year as the new supply chain model stabilizes.
  • Biologics: Expecting significant traction with 9 products in the pipeline; two launches expected in FY10.
• Risks & Contingencies:
  • Germany AOK Tender: Finalization of the tender could lead to further impairment charges on intangibles related to top products not included in the tender.
  • Currency Volatility: Significant translation losses from the Russian Ruble devaluation. Management is monitoring currency movements and may reset prices if necessary.
  • Competitive Landscape: Uncertainty regarding the launch timeline of competitors' generic versions of Sumatriptan (Imitrex).

Investor Verification Checklist

• Sumatriptan Sustainability: Verify the duration of the two-player market dynamic for Sumatriptan and the potential impact of competitor launches on margins.
• Germany Impairment: Monitor the final outcome of the AOK tender litigation and the subsequent magnitude of any impairment charges on intangible assets.
• India Supply Chain: Track the effectiveness of the new replenishment-based supply chain model in reversing the flat revenue trend in the domestic market.
• Currency Hedging: Review the company's hedging strategy and exposure to the Russian Ruble and other foreign currencies given recent volatility.
• PSAI Margins: Assess whether the decline in PSAI gross margins (27%) is a temporary anomaly or a structural shift due to input costs and product mix.